The present invention relates to 3D brain organoids, uses thereof, methods and culture medium for generating such organoids. An aspect of the invention provides brain organoids and methods of generating such organoids with bilaterally symmetric optic vesicles, containing both neuronal and non-neuronal cell types, and exhibiting functional circuitry. These organoids can be generated within short time intervals (e.g., 50 days) and therefore are useful for medical modelling and applications.

The invention provides a method for producing a cell aggregate containing a ciliary marginal zone-like structure by culturing a cell aggregate containing a retinal tissue in which Chx10 positive cells are present in a proportion of 20% or more of the tissue in a serum-free medium or serum-containing medium, each containing a substance acting on the Wnt signal pathway for only a period before the appearance of a RPE65 gene expressing cell, followed by culturing the “cell aggregate in which a RPE65 gene expressing cell does not appear” thus obtained in a serum-free medium or serum-containing medium, each not containing a substance acting on the Wnt signal pathway and so on.

Disclosed herein are methods and compositions for the cryopreservation of stem cells, such as stem-cell derived retinal pigment epithelial cells, that have been seeded onto and cultured on a substrate, such as a polymeric substrate. Such cryopreserved stem cells are useful for cell therapies, such as treatment of ocular damage or disease.

Compositions, devices, and systems comprising a corneal tissue carrier, wherein the corneal tissue carrier comprises a corneal tissue sample and a fluid; wherein the fluid comprises resazurin. Additionally, methods including measuring cell viability.

The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 400 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in direction selective retinal ganglion cells of a gene when operatively linked to a nucleic acid sequence coding for said gene.

The invention provides an isolated dehydrated corneal tissue, comprising a full thickness corneal stroma, and substantially all, or all, of the Bowman's membrane, wherein the stroma contains cellular material. Also provided is a method to product the tissue and uses of the tissue.

Provided herein are methods for generating cultivated autologous limbal epithelial cell grafts for the treatment of various disorders caused by limbal stem cell deficiency. This invention relates to methods and compositions for treating ophthalmic disorders, diseases and injuries. In particular, the field of the invention is directed to methods, kits and compositions for treating disorders, diseases, defects and injuries of the cornea and ocular surface. The present disclosure relates to preparations of cultured mammalian limbal stem cells, derived from corneal limbus tissue.

The present invention relates to a novel process of producing therapeutic GMP grade Müller cells and Miller cells obtainable therefrom, derived from stem cells using products that are free of animal-derived components. The Müller cells are suitable for treatment of eye disease, including glaucoma. There is also provided a cell culture medium.

A structured artificial construct that allows corneal endothelium to be regenerated from isolated cells outside the human or animal body is provided. The structured artificial construct is formed from a dome-shaped base body with a honeycomb structure formed in a concave side of the base body. Methods for generating the structured artificial construct are also provided.

The present invention provides a method for the normalized culturing of corneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) β signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention.